A 5-YEAR OPEN LABEL EXTENSION TO: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF ODANACATIB (MK-0822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2010
This article has no abstract
Epistemonikos ID: 310d1d88e1f3a46335f201bb35554c9244d49afe
First added on: Apr 16, 2025